Further, we provide evidence to demonstrate that nimbolide activates RECK by inhibiting miR-21 and HIF-1α under hypoxic conditions in a cellular context using the oral cancer cell lines SCC131, SCC4 and the endothelial cell line EAhy926. The gene discussed is RECK; the disease is lip and oral cavity carcinoma.